Company intelligence / Profile preview

Ilypsa

Santa Clara / San Francisco Bay Area [1], California, United Statesnodthera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Ilypsa’s lead candidate, ILY101, completed Phase 2 trials for treating hyperphosphatemia in CKD patients on hemodialysis. The company also had a second program targeting hyperkalemia. After acquisition by Amgen, further development of the phosphorus-binding polymer was discontinued despite positive Phase 2 data[4].

Therapeutic areas: Nephrology
Modalities: Non-absorbed polymeric drugs (specifically phosphate and potassium binders)
Industry: Biotech

Drug pipeline

1 asset

ILY101

Phase 2

Indications: Hyperphosphatemia, Chronic kidney disease

Partnerships

Saltigo/Lanxess for manufacturing active ingredients to FDA standards[4]Astellas Pharma licensed rights to ILY101 for Japan development[4]

Beyond the preview

Go deeper on Ilypsa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ilypsa.

Explore the full profile